(Q36577212)

15 August 2017

1 reference

title

Drug insight: using monoclonal antibodies to treat multiple sclerosis (English)

1 reference

15 August 2017

0 references

1 reference

Reinhard Hohlfeld

1

1 reference

15 August 2017

Hartmut Wekerle

series ordinal

2

1 reference

15 August 2017

publication date

1 November 2005

1 reference

Nature Clinical Practice Neurology

15 August 2017

published in

1 reference

15 August 2017

volume

1

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

34-44

1 reference

describes a project that uses

15 August 2017

1 reference

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

MRI monitoring of MS in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

Diverse targets for intervention during inflammatory and neurodegenerative phases of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

New concepts in the immunopathogenesis of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

Immunologic responses of progressive multiple sclerosis patients treated with an anti-T-cell monoclonal antibody, anti-T12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

Three or more routes for leukocyte migration into the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

An open trial of OKT3 in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

CD3-specific antibody-induced active tolerance: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

Effects of anti-CD4 antibody treatment on lymphocyte subsets and stimulated tumor necrosis factor alpha production: a study of 29 multiple sclerosis patients entered into a clinical trial of cM-T412

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

Onset of multiple sclerosis associated with anti-TNF therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

A controlled trial of natalizumab for relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

Suppressor T cells in human diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

Other therapy options and future strategies for treating patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

An open label study of the effects of rituximab in neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

Antibody-mediated suppression of Vbeta5.2/5.3(+) T cells in multiple sclerosis: results from an MRI-monitored phase II clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

Continuous cultures of fused cells secreting antibody of predefined specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

Monoclonal antibodies: the story of a discovery that revolutionized science and medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

Therapeutic antibodies for human diseases at the dawn of the twenty-first century

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

A magic bullet for cancer--how near and how far?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

Antibody humanization: a case of the 'Emperor's new clothes'?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

Therapeutic monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

Interferon beta in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

7 January 2021

Immunology of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

7 January 2021

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

1 reference

7 January 2021

Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

7 January 2021

Manipulation of T-cell responses with monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

7 January 2021

Anti-CD4 and anti-CD2 monoclonal antibody infusions in subjects with multiple sclerosis. Immunosuppressive effects and human antimouse responses

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

7 January 2021

In vivo labeling of blood T cells: rapid traffic into cerebrospinal fluid in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

7 January 2021

Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

7 January 2021

Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-gamma secreting TH1 cells in humans

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

7 January 2021

Modelling of multiple sclerosis: lessons learned in a non-human primate

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

7 January 2021

Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

7 January 2021

Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

7 January 2021

Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

7 January 2021

Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0016

7 January 2021

Identifiers

DOI

10.1038/NCPNEURO0016

1 reference

release_hkj4nptkgvg3lg5r4hat7lyl6u

15 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/hkj4nptkgvg3lg5r4hat7lyl6u

24 November 2022

mapped directly with Wikidata item

1 reference